Cover Image
市場調查報告書

醫藥品臨床試驗服務:全球市場

Pharma Clinical Trial Services: World Industry and Market Prospects 2015-2025

出版商 Visiongain Ltd 商品編碼 209076
出版日期 內容資訊 英文 236 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品臨床試驗服務:全球市場 Pharma Clinical Trial Services: World Industry and Market Prospects 2015-2025
出版日期: 2015年06月09日 內容資訊: 英文 236 Pages
簡介

本報告提供全球醫藥品臨床實驗服務全球市場調查分析、全球市場收益預測、各預測著疾病領域的承包服務預測、主要各地各國的預測、市場影響因素,及主要企業簡介等彙整、臨床實驗外包的最有希望且有利的領域,並將其結果,為您概述為以下內容。

第1章 報告概要

第2章 臨床試驗外包的簡介

  • 臨床試驗的簡史
  • 臨床試驗的設計、實行
    • 臨床試驗的階段
    • 臨床試驗的主要因素
    • 共同的實驗設計
  • 臨床研究外包
    • 實施臨床試驗的課題
    • 外包的優點

第3章 醫藥品臨床試驗服務市場

  • 醫藥品臨床試驗服務市場
    • 經濟對臨床研究外包市場的影響
    • CRO收益:各臨床實驗階段
    • 大型製藥企業CRO的主要客戶
  • 醫藥品臨床試驗服務市場預測
    • 臨床研究外包推動成長因素
    • 醫藥品臨床研究服務市場:整體收益預測
    • 成為收益最大的部門
  • 早期階段服務市場
    • 10年初期階段服務的需求增加
    • 生物科技外包初期促進階段的成長
  • 後期階段服務市場
    • 成為最大的市場部門
    • 對後期階段開發平台候補藥的關注

第4章 醫藥品臨床試驗服務:主要已發展的市場

  • 主要國家市場
  • 醫藥品臨床試驗服務:主要國家市場預測
  • 臨床試驗地的北美
  • 西歐的臨床試驗服務的展望
  • 日本受到來自近鄰的新興市場的挑戰

第5章 醫藥品臨床試驗服務:主要新興市場

  • 臨床試驗服務的主要已發展的市場
  • 新興臨床試驗服務市場的強力成長的預測
  • 亞太地區臨床試驗:新興市場預測
  • 中東歐(CEE)的臨床試驗外包
  • 南美:靠近美國是促進成長要素

第6章 臨床試驗服務的主要疾病市場部門

  • 臨床試驗的增加
  • 醫藥品臨床試驗服務市場:各治療領域
  • 醫藥品臨床試驗服務市場收益預測:各治療領域
  • 癌症臨床試驗:主要趨勢、次市場預測
  • 心血管疾病臨床試驗:主要趨勢、次市場預測
  • 中樞神經系統臨床試驗:主要趨勢、次市場預測
  • 感染疾病臨床試驗:主要趨勢、次市場預測
  • 代謝性疾病臨床試驗:主要趨勢、次市場預測
  • 治療專門知識提供專業機會

第7章 醫藥品臨床試驗服務市場:產業趨勢

  • 優勢、弱點
  • 機會、威脅
  • STEP分析
  • 影響臨床試驗的社會要素
  • 更有效的臨床實驗的技術改善
  • 臨床試驗外包的經濟討論事項
  • 影響臨床試驗的政治、規定的發展
  • 未來的CRO成長策略
  • 臨床試驗、CRO的未來
  • 生物標記是加速醫藥品開發的方便工具

第8章 臨床試驗服務業的主要CRO

  • 醫藥品臨床試驗服務市場:各企業
  • Quintiles:醫藥品臨床試驗服務市場最大企業
  • Covance被LabCorp收購
  • PPD
  • Parexel International
  • ICON
  • INC Research
  • InVentiv Health
  • PRA International
  • CMIC:在日本最大的CRO
  • Chiltern International
  • 其他多的CRO
  • 主要企業分析

第9章 調查採訪

第10章 結論

  • 臨床試驗服務市場現狀
  • 整體市場強力成長預測
  • 下10年提供更多市場成長優點的CRO在哪裡?

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0049

Clinical Trials - Discover Commercial Potentials of Outsourced Drug Testing, Benefiting Your Authority

What does the future hold for pharmaceutical clinical research providers? Visiongain's new study gives you multilevel revenue forecasts from 2015 to 2025. It explains trends, opportunities and selling prospects for that drug development and testing.

Our report predicts sales at overall world market, submarket and national level. There you find the most promising and lucrative parts of clinical trial outsourcing, helping your research and analysis. That way stay ahead, saving time and hassle, also benefiting your influence.

Clinical research organisations (CROs) and drug companies using them will benefit from expansion of that industry and market. Those technologies and outsourced services hold rising importance in pharmaceutical R&D. See why and how, finding the gains possible.

Read on, then, to explore those contracting services for benefiting medicine. Find what influences that market and see predicted revenue.

Forecasts and other analyses to help you stay ahead in knowledge

Why struggle to find information or miss data you need on clinical outsourcing and off-shoring? Instead reduce worry there, helping your searches, proposals and presentations.

So in our work discover where the money lies, and best places for business expansion. In that study you explore revenue forecasting to 2025, results and other statistics, growth rates, leading companies and market shares.

You also assess qualitative analysis (SWOT and STEP), news, business progress, outlooks and developmental needs - pharma R&D trends and demands. You find expected gains.

There you get 78 tables, 65 charts and interviews with three companies. The clinical testing market will increase its revenues from 2015 to 2025, achieving strong sales expansion. Our survey's purpose is to explain those needs, opportunities and potentials.

That way you hear what's happening, helping you stay ahead. And the following sections explain how our new investigation benefits your work.

Predictions for the world market and submarkets - what's possible?

Along with revenue prediction for the overall world market, you see individual forecasts to 2025 for nine submarkets:

  • Early phase services
  • Late phase services
  • Other related services (grouped).

You also get individual forecasts for contract clinical services at world level by therapeutic area:

  • Cancer (oncology)
  • Cardiovascular diseases
  • CNS disorders
  • Metabolic conditions
  • Infective diseases
  • Other treatment testing needs (grouped prediction).

There gain advantages by understanding trends, needs, opportunities and challenges. Our investigation shows what will stimulate and restrain CROs, helping you stay ahead in knowledge. That way, benefit your business and reputation for commercial insight.

Our work also divides its overall world sales forecast into geographical markets.

Clinical trial outsourcing - what prospects for research in leading regions and countries?

Demands worldwide from drug developers influence service providers from 2015, especially extending clinical research in developing countries. Many opportunities exist for pharmaceutical companies and contract research providers. See outlooks for clinical testing.

Our new study gives individual forecasts to 2025 for 12 national markets and a regional group, predicting overall revenues:

  • United States (US)
  • Japan
  • Germany, France, UK, Italy and Spain (EU5 countries)
  • Central and Eastern Europe (CEE, grouped forecast of that region)
  • Brazil, Russia, India and China (BRIC nations) and South Korea.

There discover progress and commercial outlooks. You assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

Forces, policies and changes from 2015 affecting clinical testing services

Our report discusses regulations, changes and other influences shaping that industry and market from 2015:

  • Future of outsourced phase I, II and III trials and post-marketing studies, inc. pharmacovigilance
  • Demand from pharmaceutical companies for drug safety and efficacy testing, including new trial designs
  • Regulations (e.g. FDA, EMA, MHLW) - policies, guidelines, ethics, changes and what they mean for that contracting industry and trial sponsors
  • Number of registered studies - present and historical trends
  • Challenges in developed and developing countries - improving systems and results
  • Adaptive trial designs for medicines and focus on late-stage R&D pipeline candidates
  • Patient recruitment and retention - overcoming challenges.

The survey also discusses these aspects of that medical research and development:

  • Social media as tools for engaging patients in trials - communications technology
  • Operational improvements for more-efficient trials - inc. electronic health records, IT advances in medical data capture, databases and cloud computing
  • Risk-sharing partnerships and agreements between CROs and pharma clients
  • CRO consolidation, specialisation and globalisation, including mergers, acquisitions and alliances, including supplier networks
  • Biological drug testing, inc. orphan drugs, biosimilars and emerging biologics - extending applications and ranges of therapeutic research
  • Biomarkers in drug development - improving the efficiency and precision of testing and data analysis, also with cost savings.

That way you find what stimulates and restrains organisations providing those testing operations, affecting their results and those of clients.

So see what the future holds. You investigate social, technological, economic and political questions, exploring companies, competition and business outlooks. Avoid falling behind.

Leading companies and 2019 market value - what revenue possible?

Our study predicts the overall world market for clinical trial services will reach $32bn in 2019, with high, fast-expanding revenues to 2025. From 2015 that outsourcing sector holds great potential for investments, developments and revenue growth. You see how it will progress.

That work profiles 14 leading CROs, ranging from global market players to regional medium-sized companies. The competitive intelligence includes these firms:

  • Quintiles
  • Laboratory Corporation of America (LabCorp)
  • Pharmaceutical Product Development (PPD)
  • Parexel International
  • ICON
  • inVentiv Health
  • PRA Health Sciences
  • Charles River Laboratories.

Also you discover interviews with three companies: Quotient Clinical, MPI Research and The Clinical Trial Company. How do CROs remain competitive? What are the secrets to their industry's progress? Find what influences clinical research contractors' success.

From 2015 to 2025, many opportunities will arise for pharma contract research organisations. Stay ahead there. Our work shows technological and commercial possibilities. It explains how professionals such as you - and their organisations - can gain.

Way Pharma Clinical Trial Services: World Industry and Market Prospects 2015-2025 helps

In these five main ways, our new study helps you gain in recognition for insight, also saving time and benefiting your authority:

  • Revenues for pharma clinical outsourcing, to 2025, at world level and for 9 submarkets - discover prospects for services, testing needs and spending trends
  • Forecasts, to 2025, for 12 countries in the Americas, Europe and Asia - explore developed and developing national markets for demand and predicted revenues
  • Prospects for established organisations, rising companies and new entrants - assess firms' portfolios, results, technologies, strategies and outlooks for success
  • Analysis of what stimulates and restrains clinical testing providers - investigate challenges, strengths and competition affecting those organisations' results
  • Interviews with that industry - discover what other experts in that field think, say and do, helping you stay ahead in technological, medical and commercial knowledge.

That report, by visiongain's in-house analysts in the UK, gives knowledge to benefit your work, saving you hassle and time. You gain data leading companies depend on.

Information found nowhere else, helping your searches, analyses, plans and presentations

That work gives independent analysis. There you get competitive intelligence found only in our report, discovering the CRO industry's most promising opportunities and financial prospects.

An off-the-shelf report can't answer every question, though our work explains that industry's structures, outlooks and potentials in depth and breadth. That's our purpose, helping you stay ahead and succeed.

With our new study you're less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, saving time, helping your business and gaining in recognition for market insight.

Trying our report now lets you discover what's possible, seeing how you can gain

Stay ahead in data. Our new investigation is for everyone assessing pharmaceutical R&D operations. For clinical testing services you explore trends, needs, opportunities and revenue potentials.

So discover what's possible and avoid missing out. Please get that report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the World Market for Pharma Clinical Trial Services
  • 1.2. Why Should You Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analysis
  • 1.5. Who Is This Study For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. An Introduction to Clinical Trial Outsourcing

  • 2.1. A Brief History of Clinical Trials
  • 2.2. Clinical Trial Design and Execution
    • 2.2.1. Phases of Clinical Trials
      • 2.2.1.1. Phase I Trials: First-In-Human Studies
      • 2.2.1.2. Phase II Trials: Proof-Of-Concept
      • 2.2.1.3. Phase III Trials: Preparing for Approval Applications
      • 2.2.1.4. Post-Marketing Studies
    • 2.2.2. Key Elements of Clinical Trials
    • 2.2.3. Common Trial Designs
      • 2.2.3.1. Improving Clinical Trial Models through Adaptive Trial Designs
  • 2.3. Clinical Trial Outsourcing
    • 2.3.1. Challenges Exist in Conducting Clinical Trials
    • 2.3.2. Benefits of Outsourcing

3. Pharma Clinical Trial Services: World Market 2015-2025

  • 3.1. The World Pharma Clinical Trial Services Market in 2013 and 2014
    • 3.1.1. The Impact of the Economy on the Clinical Trial Services Market, 2008-2014
    • 3.1.2. CRO Revenue by Trial Phase 2014
    • 3.1.3. Big Pharma Companies Are the Leading Clients for CROs
  • 3.2. The Pharma Clinical Trial Services Market 2015-2025
    • 3.2.1. What Will Drive Growth in Clinical Trial Outsourcing 2015-2025?
    • 3.2.2. The Pharma Clinical Trial Services Market: Overall Revenue Forecast 2015-2025
    • 3.2.3. Which Market Sector Will Account for the Most Revenue from 2015-2025?
  • 3.3. Early Phase Clinical Trial Services 2015-2025
    • 3.3.1. Rising Demand for Early Phase Services throughout the Decade
    • 3.3.2. Biotech Outsourcing to Drive Early Phase Growth
  • 3.4. Late Phase Clinical Trial Services 2015-2025
    • 3.4.1. Late Phase Clinical Trial Services: The Largest Market Sector 2015-2025
    • 3.4.2. Focus on Late-Stage Pipeline Candidates Early in the Decade

4. Pharma Clinical Trial Services: Leading Developed National Markets 2015-2025

  • 4.1. Leading National Markets for Pharma Clinical Trial Services 2014
  • 4.2. Pharma Clinical Trial Services: Leading National Market Forecasts 2015-2025
  • 4.3. North America as a Destination for Clinical Trials
    • 4.3.1. The US: The Largest National Market for Clinical Trial Services 2015-2025
      • 4.3.1.1. Regulatory Developments to Improve Clinical Trials in the US
    • 4.3.2. The US: Clinical Trial Service Revenue Forecast 2015-2025
  • 4.4. The Outlook for Clinical Trial Services in the EU5 2015-2025
    • 4.4.1. Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation
    • 4.4.2. EU5: Overall Market and Leading National Market Forecasts 2015-2025
    • 4.4.3. Germany Is the Largest Market for Clinical Trial Services in Western Europe
    • 4.4.4. The UK
      • 4.4.4.1. Overcoming Challenges in UK Clinical Trials
      • 4.4.4.2. UK Clinical Trial Services Market Forecast 2015-2025
    • 4.4.5. France: Market Forecast 2015-2025
    • 4.4.6. Italy: Market Forecast 2015-2025
    • 4.4.7. Spain: Market Forecast 2015-2025
  • 4.5. Japan Is Being Challenged by Neighbouring Emerging Markets
    • 4.5.1. Regulatory Policies Driving and Restraining Growth in Japan
    • 4.5.2. Growth for Clinical Trial Services in Japan 2015-2025

5. Pharma Clinical Trial Services: Leading Emerging National Markets 2015-2025

  • 5.1. Leading Emerging Markets for Clinical Trial Services 2014
    • 5.1.1. Benefits of Conducting Clinical Trials in Emerging Markets
    • 5.1.2. Challenges of Conducting Clinical Trials in Emerging Markets
  • 5.2. Strong Growth Forecast for Emerging Clinical Trial Service Markets 2015-2025
  • 5.3. Clinical Trials in Asia Pacific: An Emerging Market Perspective
    • 5.3.1. China Will be the Largest Emerging Market for Clinical Trials Services in 2025
      • 5.3.1.1. CRO Investments and Partnerships in China
      • 5.3.1.2. Chinese Clinical Trial Services Market Forecast 2015-2025
      • 5.3.1.3. China Offers Many Advantages in Clinical Trials
      • 5.3.1.4. New Guidelines by the China Food and Drug Administration (CFDA)
    • 5.3.2. India as a Hub for Clinical Trials
      • 5.3.2.1. Increasingly Strict Regulatory Procedures in India
      • 5.3.2.2. Indian Clinical Trial Services Market Forecast 2015-2025
    • 5.3.3. South Korea
      • 5.3.3.1. Improving the Appeal of South Korea
      • 5.3.3.2. Promoting Local Drug Development in South Korea
      • 5.3.3.3. Growth in the South Korean Clinical Trials Services Market 2015-2025
  • 5.4. Clinical Trial Outsourcing in Central and Eastern Europe (CEE)
    • 5.4.1. Russia
      • 5.4.1.1. Changing Clinical Trial Demands 2010-2015
      • 5.4.1.2. Russian Clinical Trial Services Market Forecast 2015-2025
    • 5.4.2. CEE: Clinical Trial Services Market Forecast 2015-2025
  • 5.5. Latin America: Proximity to the US as a Growth Driver
    • 5.5.1. Brazil: The Largest Market for Clinical Trials in Latin America 2015-2025
      • 5.5.1.1. Brazilian Clinical Trial Services Market Forecast 2015-2025

6. Leading Disease Market Sectors for Clinical Trial Services 2015-2025

  • 6.1. Rise in Clinical Trials, 2000-2015
  • 6.2. The Pharma Clinical Trial Services Market by Therapeutic Area 2014-2015
  • 6.3. The Pharma Clinical Trial Services Market: Revenue Forecasts by Therapeutic Area 2015-2025
    • 6.3.1. Imaging for CNS and Cardiovascular Clinical Trials
  • 6.4. Cancer Clinical Trials: Key Trends and Submarket Forecast 2015-2025
    • 6.4.1. Biomarkers and Companion Diagnostic Development
    • 6.4.2. Optimising Patient Recruitment and Retention
    • 6.4.3. Many Factors Complicate Cancer Clinical Trials
    • 6.4.4. Will Cancer Be the Largest Submarket for Clinical Trial Services 2015-2025?
  • 6.5. Cardiovascular Disease Clinical Trials: Key Trends and Submarket Forecast 2015-2025
    • 6.5.1. Strong Growth in the Cardiovascular Disease Clinical Trial Services Submarket 2015-2025
  • 6.6. CNS Clinical Trials: Key Trends and Submarket Forecast 2015-2025
    • 6.6.1. Late-Stage Failures in Alzheimer's Pipeline, 2009-2014
    • 6.6.2. Concerns with Placebo Response Rates in CNS Clinical Trials
      • 6.6.2.1. Cogtest Clinical: Data Capture and Cognitive Assessment
    • 6.6.3. Effective Use of Adaptive Trial Designs
    • 6.6.4. CNS Clinical Trials: Submarket Forecast 2015-2025
  • 6.7. Infectious Disease Clinical Trials: Key Trends and Submarket Forecast 2015-2025
    • 6.7.1. Challenges in the Use of Non-Inferiority Trials
    • 6.7.2. Considerations for Antibacterial Drug Clinical Trials
    • 6.7.3. Vaccine Clinical Trials and Emerging Markets
    • 6.7.4. Infectious Disease Clinical Trial Services Submarket Forecast 2015-2025
  • 6.8. Metabolic Disease Clinical Trials: Key Trends and Submarket Forecast 2015-2025
    • 6.8.1. Assessing Cardiovascular Risks in Diabetes
    • 6.8.2. Metabolic Disease Clinical Trial Services Submarket Forecast 2015-2025
  • 6.9. Therapeutic Expertise Provides an Opportunity for Specialisation
    • 6.9.1. CROs Offering Imaging Services

7. Pharma Clinical Trial Services Market: Industry Trends 2015-2025

  • 7.1. Pharma Clinical Trial Services Market: Strengths and Weaknesses 2014
  • 7.2. Pharma Clinical Trial Services Market: Opportunities and Threats 2015-2025
    • 7.2.1. Opportunities for CROs in Biosimilar Development
  • 7.3. Pharma Clinical Trial Services Market: STEP Analysis 2015-2025
  • 7.4. Social Factors Affecting Clinical Trials 2015-2025
    • 7.4.1. Drug Developers Must Deal with Ethical Considerations to Clinical Trials
    • 7.4.2. Patient Recruitment: The Leading Cause of Trial Delays
    • 7.4.3. Investing to Maintain Patient Enrolment
      • 7.4.3.1. Social Media as a Tool for Engaging Patients in Trials
  • 7.5. Improving Technology for More-Efficient Trials
    • 7.5.1. eClinical Trial Tools
      • 7.5.1.1. Electronic Health Records for Faster Patient Recruitment
    • 7.5.2. Cloud Computing as a Tool for Multicentre Trials
    • 7.5.3. Electronic Data Capture
  • 7.6. Economic Considerations for Clinical Trial Outsourcing
    • 7.6.1. Pharma is Adjusting its R&D Strategies
    • 7.6.2. CROs are Attractive for Private Investors
  • 7.7. Political and Regulatory Developments Affecting Clinical Trials
    • 7.7.1. Drug Safety and Clinical Trials Post-Approval
    • 7.7.2. Cutting Red Tape and Other Regulatory Developments
  • 7.8. Future Growth Strategies for CROs
    • 7.8.1. Strategic Partnering for Long Term Revenue Growth
      • 7.8.1.1. Sharing Risk Between Pharma and CROs
    • 7.8.2. What Strategies Are Used for Selecting a CRO?
      • 7.8.2.1. Small Pharmaceutical Companies and CROs
    • 7.8.3. CRO Consolidation is Decreasing the Number of Mid-Sized Market Players
    • 7.8.4. CROs Can Specialise to Grow
      • 7.8.4.1. Orphan Diseases Are an Opportunity for Specialisation
  • 7.9. The Future of Clinical Trials and CROs
    • 7.9.1. New Trial Designs
      • 7.9.1.1. Optimising Clinical Trials for Efficient Drug Development
    • 7.9.2. Clinical Trial Globalisation
      • 7.9.2.1. Consequences of Increased Outsourcing to Emerging Markets
    • 7.9.3. Clinical Trials Have Become Increasingly Complex
  • 7.10. Biomarkers Are Useful Tools for Accelerating Drug Development

8. Leading CROs in the Clinical Trials Services Industry in 2015

  • 8.1. The Pharma Clinical Trial Services Market by Company 2014
  • 8.2. Quintiles: The Largest Player in the Pharma Clinical Trial Services Market
    • 8.2.1. Embracing Technology for New Service Offerings
    • 8.2.2. How Quintiles Remains a Leader in the Clinical Trials Market
      • 8.2.2.1. An Increase in Emerging Biotech Customers in 2014
      • 8.2.2.2. Expanding in Developed and Emerging Markets
    • 8.2.3. Will Quintiles Remain the Market Leader to 2025?
  • 8.3. Covance Acquired by Laboratory Corporation of America (LabCorp)
    • 8.3.1. Covance Drug Development
    • 8.3.2. Covance Reorganises its Early Phase Sites
    • 8.3.3. Strong Late Phase Revenue Growth 2010-2014
    • 8.3.4. How Will Covance Drug Development Extend its Services Beyond 2014?
  • 8.4. Pharmaceutical Product Development (PPD)
    • 8.4.1. PPD: Another Global CRO to be Taken Private
    • 8.4.2. Investing in Technology for Growth
    • 8.4.3. PPD: Outlook 2015-2025
  • 8.5. Parexel International
    • 8.5.1. Parexel is Targeting Growth in Asia
    • 8.5.2. Strong Growth for Clinical Trial Services 2010-2014
    • 8.5.3. New Areas of Specialisation for Parexel
  • 8.6. ICON
    • 8.6.1. Multiple Acquisitions Have Increased ICON's Service Range
      • 8.6.1.1. Expanding Operations in China
    • 8.6.2. ICON: Recent Financial Performance and Outlook 2015-2025
  • 8.7. INC Research
    • 8.7.1. From Mid-Sized to Large CRO: INC Acquires Kendle
    • 8.7.2. INC Adds New Technological Capabilities
  • 8.8. inVentiv Health
    • 8.8.1. Four Acquisitions Move inVentiv Closer to the Big Players
    • 8.8.2. Clinical Trial Service Revenue Growth 2011 and Beyond
  • 8.9. PRA Health Sciences
    • 8.9.1. New Site Openings in Emerging Markets 2011-2014
    • 8.9.2. Future Directions for PRA Health Sciences
  • 8.10. CMIC Holdings: Japan's Largest CRO
    • 8.10.1. Increasing Asian Regional Reach
    • 8.10.2. CMIC Recent and Future Performance Analysis: An Asian Specialist
  • 8.11. Chiltern International
    • 8.11.1. Expanding into New Emerging Markets with Expansion in Israel, Taiwan and Singapore
    • 8.11.2. Chiltern International: Opportunities for Growth 2015-2025
  • 8.12. There Are Many Other CROs in the Market in 2015
    • 8.12.1. Charles River Laboratories Is an Expert in Pre-Clinical Services
    • 8.12.2. Clinipace Worldwide Is a Digital CRO
      • 8.12.2.1. Rapidly Expanding Through Acquisitions
      • 8.12.2.2. Clinipace Offers Many Technology Solutions
    • 8.12.3. Theorem Clinical Research
  • 8.12.3.1. An Established Presence in China
    • 8.12.4. WuXi PharmaTech
      • 8.12.4.1. WuXi is New to the Clinical Trial Services Market
  • 8.13. Leading Company Analysis
    • 8.13.1. Emerging Market Entry and Expansion
    • 8.13.2. How Are Global CROs Expanding Their Service Offerings and Utilising Technology?
    • 8.13.3. How Are Leading Players Seeking to Differentiate Themselves?
    • 8.13.4. Medium-Sized Players Growing Larger Through Multiple Acquisitions
    • 8.13.5. Large CROs and Strategic Partnerships with Big Pharma

9. Research Interviews from Our Survey

  • 9.1. Interview with Mark Egerton, CEO of Quotient Clinical
    • 9.1.1. Quotient Clinical's Translational Pharmaceutics Platform
    • 9.1.2. Quotient Clinical in the Global Market
    • 9.1.3. Challenges for the Pharma Clinical Trial Services Market
    • 9.1.4. Pharma Clinical Trial Services Market Size, 2015-2025
  • 9.2. Interview with Dean Knuth, Executive Director Clinical Sciences of MPI Research
    • 9.2.1. On Changes in the Outsourcing Market
    • 9.2.2. MPI Research Acquires Jasper Clinical
    • 9.2.3. Future Outlook for MPI Research
    • 9.2.4. Drivers and Restraints in Early Phase Clinical Trial Services
    • 9.2.5. Technological Advances in Clinical Trials Services
    • 9.2.6. On the Early Phase Development Market Size
  • 9.3. Interview with Ewan Campbell, Director of The Clinical Trial Company
    • 9.3.1. Clinical Trial Services Offered at TCTC
    • 9.3.2. Drivers and Restraints for Outsourcing Late-Phase Development
    • 9.3.3. Potential Impact of the EU Clinical Trial Regulation on the Clinical Trial Services
    • 9.3.4. Trends Affecting the Clinical Trial Services Market, 2015-2025

10. Conclusions from Our Research and Analysis

  • 10.1. The State of the Clinical Trial Services Market in 2014
    • 10.1.1. A Market Dominated by the Developed Countries
  • 10.2. Strong Growth for the Overall Market 2015-2025
  • 10.3. Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
    • 10.3.1. The Role of Technology in the Future of Clinical Trial Services
    • 10.3.2. How Can CROs Specialise to Remain Competitive?

List of Tables

  • Table 1.1: Pharma Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 1.2: Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014
  • Table 2.1: Founding Members of the ICH
  • Table 2.2: Types of Adaptive Trial Design
  • Table 3.1: Breakdown of Pharma Clinical Spending by Phase, 2014
  • Table 3.2: Pharma Clinical Trial Services Market by Sector, 2014
  • Table 3.3: CRO Clinical Trial Services Revenue by Customer Type, 2014
  • Table 3.4: Pharma Clinical Trial Services Market: Overall Market and Revenue Forecasts ($bn) by Sector, 2014-2025
  • Table 3.5: Clinical Trial Services Submarket Shares, 2014-2025
  • Table 3.6: Early Phase Clinical Trial Services Submarket Forecast ($bn), 2015-2025
  • Table 3.7: Late Phase Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Table 4.1: World Pharma Clinical Trial Services Market by Region, 2014
  • Table 4.2: Pharma Clinical Trial Services Market: Revenue Forecasts ($bn) by Country, 2014-2025
  • Table 4.3: Pharma Clinical Trial Services: Market Shares by Country, 2014-2025
  • Table 4.4: US Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 4.5: EU5 Clinical Trial Services Market by Country, 2014
  • Table 4.6: Number of CRO Offices in the EU5 by Country, 2015
  • Table 4.7: EU5 Clinical Trial Services Market: Revenue Forecasts ($bn) by Country, 2014-2025
  • Table 4.8: German Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 4.9: UK Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 4.10: French Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 4.11: Italian Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 4.12: Spanish Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 4.13: Japanese Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 5.1: Leading Emerging Markets for Pharma Clinical Trial Services, 2014
  • Table 5.2: Population Statistics in BRIC Nations, May 2015
  • Table 5.3: English Proficiency in Emerging Markets, 2014
  • Table 5.4: Pharma Clinical Trial Services Market: Revenue Forecasts ($bn) in Emerging Markets, 2014-2025
  • Table 5.5: Chinese Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 5.6: Indian Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 5.7: South Korean Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 5.8: Russian Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 5.9: CEE Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 5.10: Brazilian Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Table 6.1: Number of Registered Studies, 2000-2015
  • Table 6.2: Global Clinical Trials (Phase I-IV) by Therapeutic Area, 2015
  • Table 6.3: Leading Therapeutic Areas for Clinical Trial Services, 2014
  • Table 6.4: Clinical Pipelines for Leading Therapeutic Areas, Numbers of Studies, 2014
  • Table 6.5: Pharma Clinical Trial Services Market: Revenue Forecasts ($bn) for Leading Therapeutic Areas, 2014-2025
  • Table 6.6: Selected CROs Specialising in Biomarker Services, 2015
  • Table 6.7: Cancer Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
  • Table 6.8: Cancer Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Table 6.9: Cardiovascular Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Table 6.10: Cardiovascular Disease Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
  • Table 6.11: Late-Stage Pipeline Failures in Alzheimer's Disease, 2009-2014
  • Table 6.12: Approved Therapies for Alzheimer's Disease, 1996-2014
  • Table 6.13: CNS Disease Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
  • Table 6.14: CNS Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Table 6.15: Hepatitis C: Global Prevalence by Region, 2014
  • Table 6.16: Infectious Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Table 6.17: Infectious Disease Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
  • Table 6.18: Metabolic Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Table 6.19: Metabolic Disease Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
  • Table 6.20: Selected Imaging Specialist CROs, 2015
  • Table 7.1: Pharma Clinical Trial Services Market: Strengths and Weaknesses, 2014
  • Table 7.2: Pharma Clinical Trial Services Market: Opportunities and Threats, 2015-2025
  • Table 7.3: Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015
  • Table 7.4: Pharma Clinical Trial Services Market: STEP Analysis, 2015-2025
  • Table 7.5: Selected Online Communities to Aid Patient Recruitment and Trial Involvement, 2015
  • Table 7.6: Selected CROs Investing in Technology, 2011-2014
  • Table 7.7: Selected Sources of Biomarkers and Relevant Research Technology, 2015
  • Table 8.1: Revenues ($bn) of Selected CROs, 2014
  • Table 8.2: Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 8.3: Covance Drug Development: Service Revenue ($bn) by Segment, 2010-2014
  • Table 8.4: PPD: Service Revenue ($bn) and Revenue Share (%) by Sector, 2010
  • Table 8.5: Parexel International: Service Revenue by Sector ($bn) and CAGR (%), 2010- 2014 (Year Ending 30 June)
  • Table 8.6: Parexel International: Service Revenue ($bn), AGR (%), and CAGR (%), 2012- 2014 (Year Ending 31 December)
  • Table 8.7: Parexel International: Service Revenue ($bn) and Revenue Share (%) by Region, 2013 and 2014
  • Table 8.8: ICON: Service Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 8.9: ICON: Net Revenue ($bn) and CAGR (%) by Region, 2012-2014
  • Table 8.10: Kendle: Service Revenue ($bn) and AGR (%) by Sector, 2009-2010
  • Table 8.11: INC Research: Service Revenue ($bn), AGR (%), and CAGR (%), 2011-2014
  • Table 8.12: inVentiv Health: Service Revenue ($bn) and AGR (%) by Sector, Q2 2010 & Q2 2011
  • Table 8.13: PRA Health Sciences: Service Revenue ($bn), AGR (%), and CAGR (%), 2010-2014
  • Table 8.14: CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2011-2014
  • Table 8.15: Chiltern International: Therapeutic Experience
  • Table 8.16: Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014
  • Table 8.17: WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014
  • Table 8.18: Selected Strategic Partnerships Signed, 2011-2014
  • Table 10.1: Pharma Clinical Trial Services Market by Sector, 2014, 2019 & 2025

List of Figures

  • Figure 2.1: Brief History of Clinical Trials
  • Figure 3.1: Breakdown of Pharma Clinical Spending by Phase, 2014
  • Figure 3.2: Pharma Clinical Trial Services Market by Sector, 2014
  • Figure 3.3: CRO Clinical Trial Services Revenue by Customer Type, 2014
  • Figure 3.4: Clinical Trial Services Market: Drivers and Restraints, 2015-2025
  • Figure 3.5: Pharma Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 3.6: Pharma Clinical Trial Services Market by Sector, 2019
  • Figure 3.7: Pharma Clinical Trial Services Market by Sector, 2025
  • Figure 3.8: Early Phase Clinical Trial Services Submarket Forecast ($bn), 2015-2025
  • Figure 3.9: Early Phase Trial Services Submarket: Drivers and Restraints, 2015-2025
  • Figure 3.10: Late Phase Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Figure 3.11: Late Phase Trial Services Submarket: Drivers and Restraints, 2015-2025
  • Figure 4.1: World Pharma Clinical Trial Services Market by Region, 2014
  • Figure 4.2: World Pharma Clinical Trial Services Market by Region, 2019
  • Figure 4.3: World Pharma Clinical Trial Services Market by Region, 2025
  • Figure 4.4: US Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 4.5: EU5 Clinical Trial Services Market by Country, 2014
  • Figure 4.6: Number of CRO Offices in the EU5 by Country, 2015
  • Figure 4.7: EU5 Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 4.8: German Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 4.9: UK Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 4.10: French Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 4.11: Italian Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 4.12: Spanish Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 4.13: Japanese Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 5.1: Leading Emerging Markets for Pharma Clinical Trial Services, 2014
  • Figure 5.2: Cost Savings Available for Clinical Trials in Emerging Markets, 2014
  • Figure 5.3: Relative Competence in English in Emerging Markets, 2012
  • Figure 5.4: Pharma Clinical Trial Services: Emerging Market Forecasts ($bn), 2014-2025
  • Figure 5.5: Chinese Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 5.6: Indian Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 5.7: South Korean Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 5.8: Russian Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 5.9: CEE Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 5.10: Brazilian Clinical Trial Services Market Forecast ($bn), 2014-2025
  • Figure 6.1: Number of Registered Studies, 2000-2015
  • Figure 6.2: Global Clinical Trials by Therapeutic Area, 2014
  • Figure 6.3: Leading Therapeutic Areas for Clinical Trial Services, 2014
  • Figure 6.4: Leading Therapeutic Areas for Clinical Trial Services, 2014
  • Figure 6.5: Pharma Clinical Trial Services Market: Revenue Forecasts ($bn) for Leading Therapeutic Areas, 2014, 2019 & 2025
  • Figure 6.6: Cancer Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Figure 6.7: Cardiovascular Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Figure 6.8: CNS Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Figure 6.9: Hepatitis C: Global Prevalence by Region, 2014
  • Figure 6.10: Infectious Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Figure 6.11: Metabolic Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
  • Figure 7.1: The 3+3 Staging Trial Design
  • Figure 8.1: Revenues ($bn) of Selected CROs, 2014
  • Figure 8.2: Quintiles: Service Revenue ($bn) and AGR (%), 2010-2014
  • Figure 8.3: Covance Drug Development: Service Revenue ($bn) by Segment, 2010-2014
  • Figure 8.4: PPD: Service Revenue Share (%) by Sector, 2010
  • Figure 8.5: Parexel International: Service Revenue ($bn) by Sector, 2010-2014 (Year Ending 30 June)
  • Figure 8.6: Parexel International: Service Revenue ($bn) and AGR (%), 2012-2014 (Year Ending 31 December)
  • Figure 8.7: Parexel International: Service Revenue Share (%) by Region, 2014*
  • Figure 8.8: ICON: Service Revenue ($bn) and AGR (%), 2010-2014
  • Figure 8.9: ICON: Net Revenue Share (%) by Region, 2014
  • Figure 8.10: Kendle: Service Revenue Share (%) by Sector, 2010
  • Figure 8.11: INC Research: Gross and Net Service Revenue ($bn) and AGR (%), 2011-2014
  • Figure 8.12: inVentiv Health: Service Revenue ($bn) by Sector, Q2 2010 & Q2 2011
  • Figure 8.13: PRA Health Sciences: Service Revenue ($bn) and AGR (%) 2010-2014
  • Figure 8.14: CMIC: CRO Service Revenue ($bn), 2011-2014
  • Figure 8.15: Chiltern International's Clinical Trials: Therapeutic Experience
  • Figure 8.16: Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2013 and 2014
  • Figure 8.17: WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014
  • Figure 10.1: Pharma Clinical Trial Services Market by Sector, 2014, 2019 & 2025

Companies Listed

  • 3C Alliance
  • Actavis
  • Adamas Pharmaceuticals
  • Adheris (an InVentiv Health company)
  • Administration of Science, Technology and Training (ASST) [Vietnam]
  • Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
  • Agenzia Italiana del Farmaco (AIFA) [Italy]
  • Agilent Technologies
  • Agility Clinical
  • AKESOgen
  • Akos
  • Allscripts
  • Amgen
  • Aptiv Solutions (now part of ICON plc)
  • Aptuit
  • ASAN Medical Center
  • Assent Consulting
  • Associação Brasileira de CROs (Abracro)
  • Association for the Accreditation of Human Research Protection Programs (AAHRPP)
  • Association of Clinical Trial Organisations (ACTO) [Russia]
  • Astellas Pharma
  • Avista Capital Partners
  • Baxter International
  • Bayer
  • BeijingWits Medical Consulting (part of ICON)
  • Ben's Friends
  • Berry Consultants
  • BioBay
  • BioClinica
  • BioDuro (part of PPD)
  • BioDuro Biologics
  • Biogen Idec
  • Biomedical Systems
  • BioTrak
  • Bioxydyn
  • BML
  • Boehringer Ingelheim
  • Bridgepoint Development Capital
  • Bristol-Myers Squibb
  • Caprion
  • Catalent
  • Catalina Health (part of InVentiv Health)
  • Celerion
  • Center for Biologics Evaluation and Research (CBER) [US]
  • CenterWatch
  • Central Drugs Standard Control Organization (CDSCO) [India]
  • Center for Drug Evaluation (CDE)
  • Charles River Laboratories
  • China Food and Drug Administration (CFDA)
  • Chinese Ministry of Commerce
  • ClinForce
  • Clinical Trial Support
  • Clinigene International
  • Clinipace Worldwide
  • ClinStar
  • CMIC Holdings
  • CMIC (Beijing) Co
  • CNS Healthcare
  • CNS Vital Signs
  • Cogtest (part of The Cognition Group)
  • Corex Pharmaceutical
  • Council for International Organizations of Medical Sciences (CIOMS)
  • CRI Lifetree (part of PRA Health Sciences)
  • Cromos Pharma
  • CROMSOURCE
  • Cross Country Healthcare Inc
  • Czura Thornton
  • Dako (part of Agilent Technologies)
  • Department of Health [UK]
  • Department of Health and Human Services [US]
  • Drug Controller General of India (DCGI)
  • Duke Clinical Research Institute
  • EF Education First
  • Eisai
  • Ekam Imaging
  • Eli Lilly
  • EPS Corporation (now EPS Holdings, Inc.)
  • EPS Holdings, Inc.
  • European Commission
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • European Parliament
  • Firecrest Clinical (part of ICON)
  • Forest Pharmaceuticals
  • Food and Drug Administration (US FDA)
  • Frontage Laboratories
  • GCP ClinPlus
  • GE Healthcare
  • Genstar Capital
  • Global CNS Research
  • Global Research Services (GRS)
  • Glówny Urzad Statystyczny (Polish Central Statistical Office)
  • GSK
  • Harlan Laboratories (part of Huntingdon Life Sciences)
  • Hellman & Friedman
  • Hisun Pharmaceuticals
  • Hospital Italiano de Buenos Aires
  • Huntingdon Life Sciences
  • i3 Research (part of inVentiv Health)
  • ICON
  • ImageIQ
  • ImmuneHealth
  • INC Research
  • Infociencia (part of RPS)
  • Innovative Medicines Initiative (IMI)
  • Inspire
  • Institute for Medical Research Management and Biometrics (IMEREM, part of RPS)
  • Integrium
  • International Cancer Genome Consortium
  • International Conference of Harmonisation (ICH)
  • inVentiv Health
  • J&J
  • Janssen Pharmaceuticals (a subsidiary of J&J)
  • Japan Pharmaceutical Manufacturers Association (JPMA)
  • Jasper Clinical Research and Development Inc.
  • Java Clinical
  • JCL Bioassay Corporation (part of CMIC Holdings)
  • Julphar
  • Kendle (part of INC Research)
  • Kester Capital
  • Kforce
  • Kforce Clinical Research (KCR, part of inVentiv Health)
  • Kinship Technologies (part of PRA Health Sciences)
  • KKR
  • Korea Drug Development Fund (KDDF)
  • Korea Food and Drug Administration (KFDA)
  • Korea National Enterprise for Clinical Trials (KoNECT)
  • Kun Tuo (part of Quintiles)
  • L'Agence Nationale de Sécurité du Medicament (L'ANSM) [France]
  • Laboratory Corporation of America (LabCorp)
  • Les Entreprises du Médicament (LEEM)
  • LSK Global
  • MAB Discovery
  • Malaysian Biotechnology Corporation
  • Massachusetts General Hospital
  • Maximax Pharmaceutical Research
  • MDS Pharma Services (part of INC Research)
  • MedAvante
  • Medaxial
  • Medelis
  • Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
  • Medidata Solutions
  • MediMedia Pharma Solutions (now part of ICON plc)
  • Medipal Holdings
  • Medivation
  • MEK Consulting (part of INC Research)
  • Merck & Co.
  • Merck BioVentures
  • Merck KGaA
  • Metabolon
  • MetricStream
  • Ministry of Health, Labor and Welfare (MHLW, Japan)
  • Ministry of Public Health [Russia]
  • Mitsubishi Gas Chemical Company, Inc.
  • Molecular NeuroImaging
  • MorphoSys
  • MPI Research
  • MRM Proteomics
  • Myriad Genetics
  • Mytrus
  • National Cancer Institute (NCI) [US]
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Institutes of Health (NIH) [US]
  • National Taiwan University Hospital (NTUH)
  • Nautic Partners
  • NeuroImage
  • NextGen Sciences
  • Nexus Oncology, an Ockham Company (formerly Nexus Oncology)
  • NHS Research Scotland (NRS)
  • Novartis
  • Novotech
  • Ockham
  • OCT
  • Omnicare
  • Oncobiologics
  • Ontario Teachers' Pension Plan
  • Oxford Cancer Biomarkers
  • Oxford Gene Technology (OGT)
  • Oxford Outcomes (part of ICON)
  • Pacific Biomarkers
  • Paragon Biomedical (part of Clinipace Worldwide)
  • Paramax International (part of RPS)
  • Parexel International
  • PatientsLikeMe
  • Perceptive Informatics (part of Parexel)
  • PFC Pharma Focus (part of Clinipace Worldwide)
  • Pfizer
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • PharmaNet Development Group (part of inVentiv Health)
  • Pharmaron
  • PPD
  • PRA International
  • Prana Biotechnology
  • PriceSpective (part of ICON)
  • Prodia Clinical Laboratory
  • Proteome Sciences
  • ProTrials Research
  • PSR Orphan Experts
  • Psychmed (part of The Cognition Group)
  • QED Clinical Services
  • Quintiles
  • Quotient Clinical
  • RCT Logic
  • Regulus Pharmaceutical Consulting (part of Clinipace Worldwide)
  • ReSearch Pharmaceutical Services (RPS, part of PRA International)
  • Roche
  • Rules Based Medicine (now Myriad RBM, part of Myriad Genetics)
  • Samsung
  • SAS
  • Seoul National University Hospital Clinical Trial Center
  • Shanghai Clinical Research Center
  • ShangPharma
  • Shire
  • State Food and Drug Administration (SFDA) [China] (now CFDA)
  • Syngene International
  • Sugi Medical Co (part of CMIC)
  • Taijitu Biologics
  • Targos Molecular Pathology
  • Tessella
  • The Carlyle Group
  • The Clinical Trial Company
  • The Cognition Group
  • Theorem Clinical Research
  • Theradex Systems
  • Therapeutic Goods Administration (TGA) [Australia]
  • Therapharm Recherches (part of RPS)
  • Thomas H. Lee Partners
  • Tigermed Consulting
  • Timaq Medical Imaging (part of ICON)
  • Trident Clinical Research (part of INC Research)
  • UCB
  • University of Manchester
  • Veeda Clinical Research
  • Veeva Systems
  • Vigiun (part of Chiltern International)
  • VirtualScopics
  • Warburg Pincus
  • West Coast Clinical Trials (WCCT)
  • World Health Organization (WHO)
  • World Heart Foundation
  • Worldwide Clinical Research
  • WuXi AppTec
  • WuXi PharmaTech
  • Yungjin Pharmaceutical
  • Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd
Back to Top